Travel abroad is associated with a high risk of acquiring multidrug-resistant Enterobacterales (MDR-E) [i.e., extended-spectrum beta-lactamase–producing Enterobacterales (ESBL-E) and plasmid-mediated-AmpC beta-lactamase–producing Enterobacterales (pAmpC-E)]. Here, we evaluated the utility of pre-enrichment and performance of screening for MDR-E using 2 different media (ChromID-ESBL and biplate-ESBL) from 574 traveler stool samples. ESBL-E and MDR-E were detected in 49% (281/574) and 51% (296/574) of travelers, respectively. Pre-enrichment improved the detection of ESBL-E and MDR-E by 11.7% and 12.5%, respectively, without decreasing specificity (88.4% versus 87.4% for ESBL-E screening and 92.4% versus 89.9% for MDR-E screening). Sensitivity of the biplate-ESBL agar was higher than for ChromID-ESBL for ESBL-E detection (92.9% versus 86.1%), but specificity was lower (64.2% versus 87.4%). Whereas pAmpC-E were all detected by biplate-ESBL, 96% (47/49) and 82% (40/49) were detected by ChromID-ESBL, respectively, with and without pre-enrichment. Pre-enrichment increases the performance of MDR-E screening, especially in individuals with low MDR-E digestive abundance.

出国旅行与获得耐多药肠杆菌[MDR-E]（即产生广谱β-内酰胺酶的肠杆菌（ESBL-E）和质粒介导的AmpC-β-内酰胺酶的肠杆菌（pAmpC）相关的高风险-E）]。在这里，我们评估了从574个旅行者粪便样本中使用2种不同的培养基（ChromID-ESBL和biplate-ESBL）对MDR-E进行预富集的效用和筛选性能。分别在49％（281/574）和51％（296/574）的旅行者中检测到ESBL-E和MDR-E。预富集使ESBL-E和MDR-E的检出率分别提高了11.7％和12.5％，而没有降低特异性（ESBL-E筛查为88.4％对87.4％，MDR-E筛查为92.4％对89.9％）。在ESBL-E检测中，双板ESBL琼脂的灵敏度高于ChromID-ESBL（92.9％对86.1％），但特异性较低（分别为64.2％和87.4％）。尽管双板ESBL均检测到了pAmpC-E，但有和没有预富集的ChromID-ESBL分别检测到了96％（47/49）和82％（40/49）。预富集可提高MDR-E筛查的性能，特别是在MDR-E消化丰度低的个体中。